Agenus Secures Up to $340 Million Financing, Shares Surge 13%
Agenus Inc. (NASDAQ:AGEN) experienced a 13% increase in its shares during premarket trading on Monday following the announcement of an $85 million private placement. This financing is intended to enhance the company's balance sheet and facilitate the ongoing development of its clinical pipeline. The deal also includes purchase warrants that could generate an additional $255 million if fully exercised, raising the total potential value of the financing package to $340 million.
The private placement was led by Commodore Capital, with participation from both existing and new institutional investors, including RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. Agenus indicated that the proceeds from this financing will primarily be allocated to its Phase 3 ROBBIN clinical trial.
For Your Trading Desk
Sponsor Spike Success.
If all warrants are exercised, Agenus anticipates that the financing will provide sufficient cash to sustain operations through the end of 2031. In conjunction with this financing announcement, the company revealed its decision to discontinue financial support for the BATTMAN Phase 3 study, which evaluates a treatment for late-line metastatic microsatellite stable (MSS) colorectal cancer. This strategic shift reflects Agenus's intention to prioritize resources towards programs that present stronger long-term development opportunities.
The new financing arrangement offers Agenus increased flexibility as it progresses its late-stage clinical portfolio while extending its projected cash runway. Investors reacted positively to the news, resulting in a notable rise in the stock price during premarket trading after the funding package was confirmed.




